Results from a recent retrospective analysis conducted in Germany indicate that the com­bi­na­tion of Velcade plus Treanda and pred­ni­sone is effective for re­lapsed and refractory multiple myeloma pa­tients with kidney im­pair­ment.

Specifically, 67 percent of pa­tients responded to the treatment, and kidney func­tion improved in 86 percent of pa­tients. The study investigators point out that the responses were rapid, with a median time to response of three weeks.  With a median progression-free survival of 10 months, some pa­tients experienced a …